---
title: "CLSA Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296660775.md"
description: "In a report released yesterday, from CLSA maintained a Buy rating on CSPC Pharmaceutical Group, with a price target of HK$19.00.Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In a report released yesterday, Citi also maintained a Buy rating on the stock with a HK$14.00 price target."
datetime: "2026-08-22T00:26:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296660775.md)
  - [en](https://longbridge.com/en/news/296660775.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296660775.md)
generator: "portal-rs"
---

# CLSA Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)

In a report released yesterday, from CLSA maintained a Buy rating on CSPC Pharmaceutical Group, with a price target of HK$19.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

In a report released yesterday, Citi also maintained a Buy rating on the stock with a HK$14.00 price target.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug](https://longbridge.com/en/news/297512143.md)
- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [These Were The Best And Worst Performing Assets Of August](https://longbridge.com/en/news/297728245.md)
- [eDreams ODIGEO Beats Market Estimates One Quarter Into Its Peak Investment Year and Further Grows Subscribers to 8.1 Million | EDDRF Stock News](https://longbridge.com/en/news/297623101.md)
- [AcuCort notifies availability of August 2026 newsletter press release](https://longbridge.com/en/news/297505730.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**